Current therapeutic advances in patients and experimental models of Huntington's disease

Current Drug Targets

Volumn 15, Issue 3, 2014, Pages 313-334

  Brett, Ana C ^a   Rosenstock, Tatiana R ^b   Rego, A Cristina ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Huntington disease; Mutant huntingtin; Neuroprotective therapy; Symptomatic treatment

Indexed keywords

ATOMOXETINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CEP 1347; CILIARY NEUROTROPHIC FACTOR; CITALOPRAM; CLONIDINE; FLUPHENAZINE; GENE THERAPY AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; ICOSAPENTAENOIC ACID ETHYL ESTER; LEVODOPA; MERCAPTAMINE; METHAZOLAMIDE; MINOCYCLINE; MINOXIDIL; PIMOZIDE; PRAMIPEXOLE; PRIDOPIDINE; RAPAMYCIN; RESERPINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOMATOMEDIN C; SULPIRIDE; TETRABENAZINE; THIORIDAZINE; TIAPRIDE; TREHALOSE; UBIDECARENONE; UNINDEXED DRUG; VERAPAMIL;

APOPTOSIS; AUTOPHAGY; BRAIN DEPTH STIMULATION; CAG REPEAT; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DEEP BRAIN STIMULATION; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MICROSATELLITE REPEATS; NEUROPROTECTIVE AGENTS; RNA, SMALL INTERFERING;

EID: 84896718561     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450114666131124140704     Document Type: Review

References (192)

1. Ho LW, Carmichael J, Swart J, Wyttenbach A, Rankin J, Rubinsztein DC. The molecular biology of Huntington's disease. Psychol Med 2001; 31: 3-14.
2. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72(6): 971-83.
3. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 2008; 7: 2803-20.
4. Rosenstock TR, Duarte AI, Rego AC. Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease-from clinical features to the bench. Curr Drug Targets 2010; 11(10): 1218-36.
5. Rosas HD, Koroshetz WJ, Chen YI, et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003; 60(10): 1615-20.
6. Gabery S, Murphy K, Schultz K, et al. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathologicalanalyses. Acta Neuropathol 2010; 120(6): 777-88
7. Spargo E, Everall IP, Lantos PL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993; 56(5): 487-91.
8. Rosenstock TR, Brett AC, Rego AC. Neuronal pathways affected in Huntington's Disease. In: Multidisciplinary Viewpoint on Neurodegenerative Diseases 2012: 1-26.
9. Rosenstock TR, Rego AC. Modified mitochondrial dynamics, turnover and function in neurodegeneration: a focus on Huntington's Disease. In: Cellular Bioenergetics in Health and Diseases: New Perspectives in Mitochondrial Biology 2012: 149-94.
10. Squitieri F, Cannella M, Sgarbi G, et al. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev 2006; 127: 217-20.
11. Sørensen SA, Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J Med Genet 1992; 29(12): 911-4.
12. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-84.
13. Brandt J, Strauss ME, Larus J, Jensen B, Folstein SE, Folstein MF. Clinical correlates of dementia and disability in Huntington's disease. J Clin Neuropsychol 1984; 6(4): 401-12.
14. Folstein S, Abbott MH, Chase GA, Jensen BA, Folstein MF. The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med 1983; 13: 537-42.
15. Penney JB Jr, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990; 5(2): 93-9.
16. Thompson PD, Berardelli A, Rothwell JC, et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1998; 111: 223-44.
17. Garcia-Ruiz PJ, Gomez-Tortosa E, Sanchez-Bernados V, Rojo A, Fontán A, Garcia de Yebenes J. Bradykinesia in Huntington's disease. Clin Neuropharmacol 2000; 23(1): 50-2.
18. Duff K, Paulsen J, Mills J, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology 2010; 75(6): 500-7.
19. Trejo A, Boll MC, Alonso ME, Ochoa A, Velásquez L. Use of oral nutritional supplements in patients with Huntington's disease. Nutrition 2005; 21: 889-94.
20. Aziz A, Fronczek R, Maat-Schieman M, et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol 2008; 18: 474-83.
21. Pouladi MA, Xie Y, Skotte NH, et al. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 2010; 19: 1528-38.
22. Saleh N, Moutereau S, Azulay JP, et al. High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Huntington French Speaking Group. Neurology 2010; 75(1): 57-63.
23. Mochel F, Charles P, Seguin F, et al. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007; 2: e647.
24. Huntington Study Group. The Unified Huntington's Disease Rating Scale: Reliability and Consistency. Mov Dis 1996; 11: 136-42
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. In: Washington DC: U.S. Department of Health, Education and Welfare, 1976: 534-7
26. Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998; 55(6): 801-5.
27. Helder DI, Kaptein AA, van Kempen GM, van Houwelingen JC, Roos RA. Impact of Huntington's disease on quality of life. Mov Disord 2001; 16(2): 325-30.
28. Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat 2010; 6: 657-65.
29. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006; 6: 7-17.
30. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66: 366-72.
31. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 2009; 9: 62.
32. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011; 10(12): 1049-57.
33. Waugh JL, Miller VS, Chudnow RS, Dowling MM. Juvenile Huntington disease exacerbated by methylphenidate: case report. J Child Neurol 2008; 23: 807-9.
34. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008; 5: 181-97.
35. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988; 38: 84-8.
36. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984; 47: 844-7.
37. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984; 9: 329-38.
38. Roos RA, Buruma OJ, Bruyn GW, Kemp B, van der Velde EA. Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982; 65: 45-50.
39. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12: 2701-20.
40. Rollema H, Skolnik M, D'Engelbronner J, Igarashi K, Usuki E, Castagnoli NJr. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and In vitro mitochondrial studies. J Pharmacol Exp Ther 1994; 268(1): 380-7.
41. Iwahashi K, Anemo K, Nakamura K, Fukunishi I, Igarashi K. Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism. Neuropsychobiology 2001; 44(3): 126-8.
42. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-11.
43. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63: 35-9.
44. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 2002; 25(5): 263-65.
45. Bonelli RM, Hofmann P. A review of the treatment options for Huntington's disease. Expert Opin Pharmacother 2004; 5: 767-76.
46. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry 2008; 20: 1-3
47. Bonelli RM, Mayr BM, Niederwieser G, Reisecker F, Kapfhammer HP. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol 2003; 17: 459-60.
48. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006; 47: 70-2.
49. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59: 694-9.
50. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003; 61: 1551-6.
51. Landwehrmeyer GB, Dubois B, de Yébenes JG. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007; 62: 262-72.
52. Joshi PR, Wu NP, André VM, et al. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 2009; 29: 2414-27.
53. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 2007; 64: 2090-103.
54. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich J. Dosedependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington's disease patients: a case series. BMC Neurol 2006; 6: 11.
55. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 2009; 29: 484-7.
56. Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 2007; 8: 141-53.
57. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington's disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 69-72.
58. Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, Bartlett PF, Hannan AJ. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 2005; 22(8): 2081-8.
59. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
60. Slow EJ, van Raamsdonk J, Rogers D, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003; 12: 1555-67.
61. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009; 132(Pt 4): 919-32.
62. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci 1996; 8: 338-40.
63. Pang TY, Du X, Zajac MS, Howard ML, Hannan AJ. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 2009; 18(4):753-66.
64. Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's Disease. Neurobiol Dis 2008; 30: 312-22.
65. Schilling G, Becher MW, Sharp AH, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant Nterminal fragment of huntingtin. Hum Mol Genet 1999; 8: 397-407.
66. Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004; 56(2): 290-4.
67. Fawcett AP, Moro E, Lang AE, Lozano AM, Hutchison WD. Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. Mov Disord 2005; 20(3): 371-7.
68. Hebb MO, Garcia R, Gaudet P, Mendez IM. Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report. Neurosurgery 2006; 58(2): E383.
69. Temel Y, Cao C, Vlamings R, et al. Motor and cognitive improvement by deep brain stimulation in a transgenic rat model of Huntington's disease. Neurosci Lett 2006; 406(1-2): 138-41.
70. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413: 739-43.
71. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 2041-6.
72. Mielcarek M, Benn CL, Franklin SA, et al. SAHA decreases HDAC 2 and 4 levels In vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington'sdisease. PLoS One 2011; 6(11): e27746.
73. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23: 9418-27.
74. Ryu H, Lee J, Olofsson BA, et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 2003; 100: 4281-6.
75. Oliveira JM, Chen S, Almeida S, et al. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 2006; 26: 11174-86.
76. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005; 280: 556-63.
77. Thomas EA, Coppola G, Desplats PA, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008; 105: 15564-9.
78. Dompierre JP, Godin JD, Charrin BC, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007; 27: 3571-83.
79. Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington's disease: a dose-finding study. Mov Disord 2007; 22: 1962-4.
80. Tang BL, Chua CE. SIRT1 and neuronal diseases. Mol Aspects Med 2008; 29: 187-200.
81. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab 2006; 4: 349-62.
82. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1TTTby mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
83. Parker JA, Arango M, Abderrahmane S, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 2005; 37: 349-50.
84. Candelario-Jalil E, de Oliveira AC, Gräf S, et al. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 2007; 10: 4-25.
85. Richard T, Pawlus AD, Iglésias ML, et al. Neuroprotective properties of resveratrol and derivatives. Ann NY Acad Sci 2011; 1215: 103-8.
86. Huang SS, Tsai MC, Chih CL, Hung LM, Tsai SK. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci 2001; 69: 1057-65.
87. Pallàs M, Verdaguer E, Tajes M, Gutierrez-Cuesta J, Camins A. Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov 2008; 3: 61-9.
88. Luthi-Carter R, Taylor DM, Pallos J, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010; 107: 7927-32.
89. Zuccato C, Tartari M, Crotti A, et al. Huntingtin interacts with REST NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003; 35: 76-83.
90. Gauthier LR, Charrin BC, Borrell-Pagès M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-38.
91. Canals JM, Pineda JR, Torres-Peraza JF, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci 2004; 24: 7727-39.
92. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B. Brain-derived neurotrophic factor over-expressionin the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem 2008; 105: 369-79.
93. Alberch J, Pérez-Navarro E, Canals JM. Neurotrophic factors in Huntington's disease. Prog Brain Res 2004; 146: 195-229.
94. Almeida S, Laço M, Cunha-Oliveira T, Oliveira CR, Rego AC. BDNF regulates BIM expression levels in 3-nitropropionic acidtreated cortical neurons. Neurobiol Dis 2009; 35: 448-56.
95. Almeida S, Cunha-Oliveira T, Laço M, Oliveira CR, Rego AC. Dysregulation of CREB activation and histone acetylation in 3-nitropropionic acid-treated cortical neurons: prevention by BDNF and NGF. Neurotox Res 2010; 17: 399-405.
96. Cho SR, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J Clin Invest 2007; 117: 2889-902.
97. Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2010; 30(44): 14708-18.
98. Spires TL, Grote HE, Varshney NK, et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 2004; 24: 2270-66.
99. Visanji NP, Orsi A, Johnston TH, et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008; 22: 2488-97.
100. Simmons DA, Rex CS, Palmer L, et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci USA 2009; 106: 4906-11.
101. Apostol BL, Simmons DA, Zuccato C, et al. CEP-1347 reduces mutant huntingtin associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol Cell Neurosci 2008; 39: 8-20.
102. Ginés S, Bosch M, Marco S, et al. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci 2006; 23: 649-58.
103. Ginés S, Paoletti P, Alberch J. Impaired TrkB-mediated ERK1/2 activation in Huntington's disease knock-in striatal cells involves reduced p52/p46 Shc expression. J Biol Chem 2010; 285: 21537-48.
104. McBride JL, During MJ, Wuu J, Chen EY, Leurgans SE, Kordower JH. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 2003; 181(2): 213-23.
105. Kells AP, Fong DM, Dragunow M, During MJ, Young D, Connor B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 2004; 9(5): 682-8.
106. Popovic N, Maingay M, Kirik D, Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Exp Neurol 2005; 193: 65-74.
107. McBride JL, Ramaswamy S, Gasmi M, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2006; 103(24): 9345-50.
108. Ebert AD, Barber AE, Heins BM, Svendsen CN. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease. Exp Neurol 2010; 224(1): 155-62.
109. Pineda JR, Rubio N, Akerud P, et al. Neuroprotection by GDNFsecreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther 2007; 14: 118-28.
110. Régulier E, Pereira de Almeida L, Sommer B, Aebischer P, Déglon N. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum Gene Ther 2002; 13: 1981-90.
111. Zala D, Bensadoun JC, Pereira de Almeida L, et al. Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Exp Neurol 2004; 185: 26-35.
112. Zala D, Benchoua A, Brouillet E, et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 2005; 20: 785-98.
113. Emerich DF, Winn SR. Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum. Cell Transplant 2004; 13: 253-9.
114. Bloch J, Bachoud-Lévi AC, Déglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004; 15: 968-75.
115. Sadagurski M, Cheng Z, Rozzo A, et al. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 2011; 121(10): 4070-81.
116. Duarte AI, Petit GH, Ranganathan S, et al. IGF-1 protects against diabetic features in an In vivo model of Huntington's disease. Exp Neurol 2011; 231(2): 314-9.
117. Lopes C, Ribeiro M, Duarte A, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC. IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice. Mol Neurobiol 2013; [E-pub ahead of print].
118. Escartin C, Boyer F, Bemelmans AP, Hantraye P, Brouillet E. Insulin growth factor-1 protects against excitotoxicity in the rat striatum. Neuroreport 2004; 15: 2251-54.
119. Humbert S, Bryson EA, Cordelières FP, et al. The IGF-1/Akt Pathway is neuroprotective in Huntington's Disease and involves huntingtin phosphorylation by Akt. Dev Cell 2002; 2: 831-7.
120. Yamamoto A, Cremona ML, Rothman JE. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulinsignalling pathway. J Cell Biol 2006; 172: 719-31.
121. Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther 2005; 108: 193-207.
122. Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochem Biophys Res Commun 2002; 290: 47-52.
123. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20: 4389-97.
124. Dedeoglu A, Kubilus JK, Yang L, et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 2003; 85: 1359-67.
125. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003; 61: 925-30.
126. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 2010; 16(2):183-8
127. Smith KM, Matson S, Matson WR, et al. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 616-26.
128. Ferrante RJ, Andreassen OA, Dedeoglu A, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002; 22: 1592-1599.
129. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57: 397-404.
130. Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 373-80.
131. Yang L, Calingasan NY, Wille EJ, et al. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 2009; 109: 1427-39.
132. Hyson HC, Kieburtz K, Shoulson I, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord 2010; 25(12): 1924-28.
133. Serhan CN, Chiang N. Endogenous proresolving and antiinflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 2008; 153: S200-15.
134. Murck H, Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull 2007; 72: 159-64.
135. Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 2005; 196(2): 266-72.
136. Puri BK, Bydder GM, Manku MS, Clarke A, Waldman AD, Beckmann CF. Reduction in cerebral atrophy associated with ethyleicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res 2008; 36(5): 896-905.
137. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65: 1582-9.
138. Wheeler VC, Gutekunst CA, Vrbanac V, et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 2002; 11: 633-40.
139. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801.
140. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspaseindependent and-dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 10483-7.
141. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003; 54: 186-96.
142. Huntington Study Group. Minocycline safety and tolerability in Huntington disease. Neurology 2004; 63: 547-9.
143. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 2004; 19: 692-5.
144. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004; 19: 337-42.
145. Huntington Sudy Group DOMINO Investigators. A futility study of minocycline in Huntington's disease. Mov Disord 2010; 25(13): 2219-24.
146. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci USA 2002; 99: 10671-6.
147. Wang X, Zhu S, Pei Z, et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci 2008; 28: 9473-85.
148. Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-91.
149. Uribe V, Wong BK, Graham RK, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Hum Mol Genet 2012; 21(9): 1954-67.
150. Landles C, Weiss A, Franklin S, Howland D, Bates G. Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS Curr 2012; 4: e4fd085bfc9973.
151. Gafni J, Papanikolaou T, Degiacomo F, et al. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J Neurosci 2012; 32(22): 7454-65.
152. Chu W, Rothfuss J, Chu Y, Zhou D, Mach RH. Synthesis and In vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J Med Chem 2009; 52: 2188-91.
153. Zheng S, Clabough EB, Sarkar S, Futter M, Rubinsztein DC, Zeitlin SO. Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice. PLoS Genet 2010; 6: e1000838.
154. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-95.
155. Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 2010; 13(5): 567-76.
156. Williams A, Sarkar S, Cuddon P, et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol 2008; 4: 295-305.
157. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282: 5641-52.
158. Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10: 148-54.
159. Kahlem P, Green H, Djian P. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1998; 1: 595-601.
160. Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002; 22: 8942-50.
161. Wang X, Sarkar A, Cicchetti F, et al. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 2005; 231(1-2): 57-66.
162. van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem 2005; 95(1): 210-20.
163. Mao Z, Choo YS, Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci 2006; 23(7): 1701-10.
164. Borrell-Pagès M, Canals JM, Cordelières FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006; 116: 1410-24.
165. Imarisio S, Carmichael J, Korolchuk V, et al. Huntington's disease: from pathology and genetics to potential therapies. Biochem J 2008; 412: 191-209.
166. Gardoni F, Di Luca M. New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 2006; 545: 2-10.
167. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005; 2: 155-65.
168. Lee ST, Chu K, Park JE. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Res 2006; 1118: 199-207.
169. Milnerwood AJ, Gladding CM, Pouladi MA, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010; 65: 178-90.
170. Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009; 15: 1407-13.
171. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007; 13: 453-4.
172. Popoli P, Blum D, Martire A, Ledent C, Ceruti S, Abbracchio MP. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol 2007; 81: 331-48.
173. Chou SY, Lee YC, Chen HM, et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 2005; 93: 310-20.
174. Domenici MR, Scattoni ML, Martire A, et al. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice. Neurobiol Dis 2007; 28: 197-205.
175. Potenza RL, Tebano MT, Martire A, et al. Adenosine A(2A) receptors modulate BDNF both in normal conditions and in experimental models of Huntington's disease. Purinergic Signal 2007; 3: 333-8.
176. Kieburtz K, McDermott MP, Voss TS, et al. A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Arch Neurol 2010; 67: 154-60.
177. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 2008; 3: 15.
178. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 2001; 939: 425-35.
179. Gil JM, Rego AC. The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease. Brain Res Rev 2009; 59: 410-31.
180. Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci Res 2005; 53: 241-9.
181. DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007; 104: 17204-9.
182. Huang B, Schiefer J, Sass C, Landwehrmeyer GB, Kosinski CM, Kochanek S. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load In vitro and In vivo. Hum Gene Ther 2007; 18: 303-11.
183. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6: 919-30.
184. Grondin R, Kaytor MD, Ai Y, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 2012; 135(Pt 4): 1197-209.
185. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003; 100: 7195-200.
186. Liu W, Kennington LA, Rosas HD, et al. Linking SNPs to CAG repeat length in Huntington's disease patients. Nat Methods 2008; 5: 951-3.
187. Van Bilsen PH, Jaspers L, Lombardi MS, Odekerken JC, Burright EN, Kaemmerer WF. Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther 2008; 19: 710-9.
188. Lombardi MS, Jaspers L, Spronkmans C, et al. A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009; 217: 312-9.
189. Pfister EL, Kennington L, Straubhaar J, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009; 19: 774-8.
190. Hu J, Matsui M, Gagnon KT, et al. Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 2009; 27: 478-84.
191. Silva AC, Almeida S, Laço M, et al. Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington's disease carriers. Mitochondrion 2013; 13(6): 801-9.
192. Beglinger LJ, O'Rourke JJ, Wang C, et al. Earliest functional declines in Huntington disease. Psychiatry Res 2010; 178: 414-8